Ironwood Pharmaceuticals, Inc. - financials
$4.16+0.97%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296.2M | $351.4M | $442.7M | $410.6M | $413.8M | $389.5M | $428.4M | $346.6M | $298.3M | $274.0M |
| Gross profit | $296.2M | $351.4M | $442.7M | $410.6M | $413.8M | $386.4M | $404.5M | $313.9M | $279.2M | $272.1M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.2% | 94.4% | 90.6% | 93.6% | 99.3% |
| Operating income | $98.5M | $93.1M | -$945.4M | $250.3M | $232.3M | $142.9M | $120.1M | -$150.7M | -$15.4M | -$51.9M |
| Net income | $24.0M | $880.0K | -$1.00B | $175.1M | $528.4M | $106.2M | $21.5M | -$282.4M | -$116.9M | -$81.7M |
| Net margin | 8.1% | 0.3% | −226.4% | 42.6% | 127.7% | 27.3% | 5.0% | −81.5% | −39.2% | −29.8% |
| Diluted EPS | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 | $0.66 | $0.14 | $-1.85 | $-0.78 | $-0.56 |
| EBITDA | $120.6M | $97.7M | $169.9M | $251.8M | $233.8M | $161.9M | $125.8M | -$3.0M | -$33.7M | -$30.4M |
| Operating cash flow | $127.0M | $103.5M | $183.4M | $273.8M | $261.9M | $168.8M | $10.7M | -$70.9M | -$69.4M | -$25.9M |
| Free cash flow | $127.0M | $103.4M | -$842.9M | $273.6M | $261.6M | $167.0M | $3.5M | -$71.2M | -$72.2M | -$30.1M |
| Diluted shares | 163.0M | 160.1M | 155.4M | 186.3M | 164.4M | 160.7M | 156.0M | 152.6M | 149.0M | 144.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $215.5M | $88.6M | $92.2M | $656.2M | $620.1M | $362.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $584.7M | $584.0M | $697.9M | $396.3M | $454.2M | $430.3M |
| Total assets | $396.9M | $350.9M | $471.1M | $1.10B | $1.13B | $559.2M |
| Total liabilities | $658.7M | $652.2M | $817.4M | $448.1M | $521.0M | $496.6M |
| Shareholders' equity | -$261.8M | -$301.3M | -$346.3M | $652.4M | $605.9M | $62.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology